ArticleFrontiers in psychiatry2026
Reconsidering the usefulness of using long-acting injectable buprenorphine as a tapering tool: a case report of delayed withdrawal months after last dose.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Long-acting injectable buprenorphine (LAIB) has generated enthusiasm as a potential tapering strategy for patients seeking discontinuation from buprenorphine therapy. The rationale is pharmacokinetic: gradual decline in plasma concentrations over months may blunt or prevent withdrawal. Yet protocols, clinical risks, and the characteristics of delayed withdrawal during LAIB tapers are poorly described. Case: We report a 45-year-old man who developed somatic withdrawal symptoms four months after receiving a single 200 mg dose of LAIB (Sublocade) as a tapering tool following years of stability on sublingual buprenorphine. Administration of 12.5 mg naltrexone precipitated a clinically significant worsening of withdrawal, supporting ongoing μ-opioid receptor agonism at month four. Symptoms were attenuated with transdermal buprenorphine (20 mcg/hr) as rescue therapy. Interpretation: This case underscores under-recognized risks of delayed withdrawal during LAIB-facilitated discontinuation and illustrates how loss of kappa opioid receptor (KOR) antagonism may contribute to the emergence or exacerbation of mood-like symptoms (e.g., anhedonia, dysphoria) that can be misattributed to primary psychiatric disorders rather than atypical withdrawal. Implications: Comprehensive tapering protocols, extended monitoring (6-12 months), reinforcement of recovery capital (defined as the sum of internal and external resources that support sustained recovery), and explicit informed consent about delayed withdrawal are essential when considering LAIB to discontinue buprenorphine. Clinicians should anticipate the need for bridging strategies, including symptomatic agents (such as clonidine or gabapentin), or buprenorphine rescue (temporary or return to maintenance)-and weigh formulation differences (Sublocade vs Brixadi) when planning stepwise tapers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.